Literature DB >> 26878170

Measles virus nucleocapsid protein increases osteoblast differentiation in Paget's disease.

Jumpei Teramachi, Yuki Nagata, Khalid Mohammad, Yuji Inagaki, Yasuhisa Ohata, Theresa Guise, Laëtitia Michou, Jacques P Brown, Jolene J Windle, Noriyoshi Kurihara, G David Roodman.   

Abstract

Paget's disease (PD) is characterized by focal and dramatic bone resorption and formation. Treatments that target osteoclasts (OCLs) block both pagetic bone resorption and formation; therefore, PD offers key insights into mechanisms that couple bone resorption and formation. Here, we evaluated OCLs from 3 patients with PD and determined that measles virus nucleocapsid protein (MVNP) was expressed in 70% of these OCLs. Moreover, transgenic mice with OCL-specific expression of MVNP (MVNP mice) developed PD-like bone lesions that required MVNP-dependent induction of high IL-6 expression levels in OCLs. In contrast, mice harboring a knockin of p62P394L (p62-KI mice), which is the most frequent PD-associated mutation, exhibited increased bone resorption, but not formation. Evaluation of OCLs from MVNP, p62-KI, and WT mice revealed increased IGF1 expression in MVNP-expressing OCLs that resulted from the high IL-6 expression levels in these cells. IL-6, in turn, increased the expression of coupling factors, specifically ephrinB2 on OCLs and EphB4 on osteoblasts (OBs). IGF1 enhanced ephrinB2 expression on OCLs and OB differentiation. Importantly, ephrinB2 and IGF1 levels were increased in MVNP-expressing OCLs from patients with PD and MVNP-transduced human OCLs compared with levels detected in controls. Further, anti-IGF1 or anti-IGF1R blocked Runx2 and osteocalcin upregulation in OBs cocultured with MVNP-expressing OCLs. These results suggest that in PD, MVNP upregulates IL-6 and IGF1 in OCLs to increase ephrinB2-EphB4 coupling and bone formation.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26878170      PMCID: PMC4767344          DOI: 10.1172/JCI82012

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  33 in total

1.  EphrinB2 signaling in osteoblasts promotes bone mineralization by preventing apoptosis.

Authors:  Stephen Tonna; Farzin M Takyar; Christina Vrahnas; Blessing Crimeen-Irwin; Patricia W M Ho; Ingrid J Poulton; Holly J Brennan; Narelle E McGregor; Elizabeth H Allan; Huynh Nguyen; Mark R Forwood; Liliana Tatarczuch; Eleanor J Mackie; T John Martin; Natalie A Sims
Journal:  FASEB J       Date:  2014-06-30       Impact factor: 5.191

2.  Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis.

Authors:  Chen Zhao; Naoko Irie; Yasunari Takada; Kouji Shimoda; Takeshi Miyamoto; Toru Nishiwaki; Toshio Suda; Koichi Matsuo
Journal:  Cell Metab       Date:  2006-08       Impact factor: 27.287

3.  Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone.

Authors:  Nancy Laurin; Jacques P Brown; Jean Morissette; Vincent Raymond
Journal:  Am J Hum Genet       Date:  2002-04-30       Impact factor: 11.025

4.  Osteoprotection by semaphorin 3A.

Authors:  Mikihito Hayashi; Tomoki Nakashima; Masahiko Taniguchi; Tatsuhiko Kodama; Atsushi Kumanogoh; Hiroshi Takayanagi
Journal:  Nature       Date:  2012-05-03       Impact factor: 49.962

5.  Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget's disease of bone.

Authors:  C Menaa; S V Reddy; N Kurihara; H Maeda; D Anderson; T Cundy; J Cornish; F R Singer; J M Bruder; G D Roodman
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

6.  A SQSTM1/p62 mutation linked to Paget's disease increases the osteoclastogenic potential of the bone microenvironment.

Authors:  Yuko Hiruma; Noriyoshi Kurihara; Mark A Subler; Hua Zhou; Christina S Boykin; Heju Zhang; Seiichi Ishizuka; David W Dempster; G David Roodman; Jolene J Windle
Journal:  Hum Mol Genet       Date:  2008-09-02       Impact factor: 6.150

7.  Role of TAFII-17, a VDR binding protein, in the increased osteoclast formation in Paget's Disease.

Authors:  Noriyoshi Kurihara; Sakamuri V Reddy; Norie Araki; Seiichi Ishizuka; Keiichi Ozono; Jillian Cornish; Tim Cundy; Frederick R Singer; G David Roodman
Journal:  J Bone Miner Res       Date:  2004-03-15       Impact factor: 6.741

Review 8.  Paget's disease of bone: clinical features and treatment.

Authors:  A J Zajac; P E Phillips
Journal:  Clin Exp Rheumatol       Date:  1985 Jan-Mar       Impact factor: 4.473

9.  Anabolic effects of IGF-1 signaling on the skeleton.

Authors:  Candice G T Tahimic; Yongmei Wang; Daniel D Bikle
Journal:  Front Endocrinol (Lausanne)       Date:  2013-02-04       Impact factor: 5.555

Review 10.  Eph receptors and ephrin signaling pathways: a role in bone homeostasis.

Authors:  Claire M Edwards; Gregory R Mundy
Journal:  Int J Med Sci       Date:  2008-09-03       Impact factor: 3.738

View more
  14 in total

1.  Osteoclast-derived IGF1 is required for pagetic lesion formation in vivo.

Authors:  Kazuaki Miyagawa; Yasuhisa Ohata; Jesus Delgado-Calle; Jumpei Teramachi; Hua Zhou; David D Dempster; Mark A Subler; Jolene J Windle; John M Chirgwin; G David Roodman; Noriyoshi Kurihara
Journal:  JCI Insight       Date:  2020-03-26

Review 2.  Paget's Disease of Bone.

Authors:  Luigi Gennari; Domenico Rendina; Alberto Falchetti; Daniela Merlotti
Journal:  Calcif Tissue Int       Date:  2019-01-23       Impact factor: 4.333

3.  NFAM1 signaling enhances osteoclast formation and bone resorption activity in Paget's disease of bone.

Authors:  Yuvaraj Sambandam; Kumaran Sundaram; Takamitsu Saigusa; Sundaravadivel Balasubramanian; Sakamuri V Reddy
Journal:  Bone       Date:  2017-05-12       Impact factor: 4.398

4.  Global deletion of Optineurin results in altered type I IFN signaling and abnormal bone remodeling in a model of Paget's disease.

Authors:  Henry C Tseng; Ching-Chang Ko; Jennifer Martinez; Sing-Wai Wong; Bo-Wen Huang; Xiangxiang Hu; Eui Ho Kim; Joseph P Kolb; Ricardo J Padilla; Peng Xue; Lufei Wang; Thomas H Oguin; Patricia A Miguez
Journal:  Cell Death Differ       Date:  2019-05-10       Impact factor: 15.828

Review 5.  Effects of GH/IGF axis on bone and cartilage.

Authors:  Manisha Dixit; Sher Bahadur Poudel; Shoshana Yakar
Journal:  Mol Cell Endocrinol       Date:  2020-10-14       Impact factor: 4.102

6.  Measles virus nucleocapsid protein modulates the Signal Regulatory Protein-β1 (SIRPβ1) to enhance osteoclast differentiation in Paget's disease of bone.

Authors:  Kumaran Sundaram; Yuvaraj Sambandam; Srinivasan Shanmugarajan; D Sudhaker Rao; Sakamuri V Reddy
Journal:  Bone Rep       Date:  2016-06-14

7.  A FKBP5 mutation is associated with Paget's disease of bone and enhances osteoclastogenesis.

Authors:  Bingru Lu; Yulian Jiao; Yinchang Wang; Jing Dong; Muyun Wei; Bin Cui; Yafang Sun; Laicheng Wang; Bingchang Zhang; Zijiang Chen; Yueran Zhao
Journal:  Exp Mol Med       Date:  2017-05-19       Impact factor: 8.718

Review 8.  Clinical and Genetic Advances in Paget's Disease of Bone: a Review.

Authors:  N Alonso; I Calero-Paniagua; J Del Pino-Montes
Journal:  Clin Rev Bone Miner Metab       Date:  2016-12-19

9.  The Recombinant Protein EphB4-Fc Changes the Ti Particle-Mediated Imbalance of OPG/RANKL via EphrinB2/EphB4 Signaling Pathway and Inhibits the Release of Proinflammatory Factors In Vivo.

Authors:  Yu-Wei Ge; Kai Feng; Xiao-Liang Liu; Hong-Fang Chen; Zhen-Yu Sun; Cai-Feng Wang; Zhi-Qing Liu; Hao-Wei Wang; Jing-Wei Zhang; De-Gang Yu; Yuan-Qing Mao
Journal:  Oxid Med Cell Longev       Date:  2020-06-05       Impact factor: 6.543

10.  Aplidin (plitidepsin) is a novel anti-myeloma agent with potent anti-resorptive activity mediated by direct effects on osteoclasts.

Authors:  Jesus Delgado-Calle; Noriyoshi Kurihara; Emily G Atkinson; Jessica Nelson; Kazuaki Miyagawa; Carlos Maria Galmarini; G David Roodman; Teresita Bellido
Journal:  Oncotarget       Date:  2019-04-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.